GLPwatch
The mechanistic role of tirzepatide in atherosclerosis: A review.
Int J Biol Macromol · 2025
Last updated 2026-05-28Atherosclerosis, a major cause of death, involves the buildup of fats and other substances in the arteries, often linked to obesity, type 2 diabetes, and inflammation. Tirzepatide, a drug approved for managing obesity and type 2 diabetes, has been shown to reduce inflammation related to atherosclerosis, though its exact mechanism is still being studied.
AI summary of the abstract below.
| Journal | Int J Biol Macromol, 2025 |
|---|---|
| Citations | 2 |
| Molecules | tirzepatide |
| Conditions studied | Cardiovascular Risk Reduction |
Abstract
Atherosclerosis is the leading cause of death worldwide, characterized by progressive deposition of lipids, fibrous elements, and calcification in the large arteries. The pathophysiology of atherosclerosis is complex and related to diverse mechanisms. Prominently, obesity, type 2 diabetes (T2D), and associated inflammation are common modifiable risk factors implicated in the pathogenesis of atherosclerosis. Henceforth, targeting of obesity, T2D, and linked inflammation may reduce risk for the development and progression of atherosclerosis. Researchers have demonstrated that tirzepatide, a recently approved drug for managing obesity and T2D, can reduce inflammatory changes in atherosclerosis. Nevertheless, the fundamental mechanism of tirzepatide against atherosclerosis is not completely clarified. Consequently, this review aims to discuss the mechanism of tirzepatide against atherosclerosis.
Verbatim abstract via PubMed 40972917 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.